{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T06:46:52Z","timestamp":1793774812135,"version":"4.6.1"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,4,12]],"date-time":"2023-04-12T00:00:00Z","timestamp":1681257600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>\n                      Clinical remission as a multicomponent treatment goal in severe asthma is being explored in clinical practice. This\n                      <jats:italic>post hoc<\/jats:italic>\n                      analysis used data from the REDES study to assess the proportion of patients with severe eosinophilic asthma achieving our multicomponent definitions of clinical remission after 1 year of mepolizumab treatment.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The real-world, retrospective observational REDES study enrolled patients with severe eosinophilic asthma who were newly prescribed mepolizumab and with \u226512 months of medical records pre-enrolment. Multicomponent clinical remission was defined as: oral corticosteroid (OCS)-free; exacerbation-free; asthma control test (ACT) score \u226520; and with or without post-bronchodilator forced expiratory volume in 1 second \u226580%. Baseline characteristics were also assessed in those who did\/did not achieve clinical remission.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>37% and 30% of patients with severe eosinophilic asthma met our proposed three- and four-component on-treatment clinical remission definitions; an increase from 2% and 3% at baseline. Most frequently achieved individual components of clinical remission were: OCS-free; ACT score \u226520. For patients fulfilling the multicomponent clinical remission definitions, at baseline we observed higher blood eosinophil counts, better ACT scores and lung function, lower maintenance OCS use, and a slightly lower rate of prior exacerbations versus those who did not.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Clinical remission is a realistic target in clinical practice for a subset of patients with severe eosinophilic asthma receiving mepolizumab. Further studies are required to elucidate whether features linked to the underlying endotype can help predict treatment outcomes, increase rates of clinical remission, and potentially modify disease progression.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2023.1150162","type":"journal-article","created":{"date-parts":[[2023,4,12]],"date-time":"2023-04-12T07:02:49Z","timestamp":1681282969000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":132,"title":["Remission outcomes in severe eosinophilic asthma with mepolizumab therapy: Analysis of the REDES study"],"prefix":"10.3389","volume":"14","author":[{"given":"Ian","family":"Pavord","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frances","family":"Gardiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liam G.","family":"Heaney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Domingo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert G.","family":"Price","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Pullan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Oppenheimer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy","family":"Brusselle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Nagase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey","family":"Chupp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilio","family":"Pizzichini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Ba\u00f1as-Conejero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Howarth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,4,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/S0140-6736(17)30879-6","article-title":"After asthma: redefining airways diseases","volume":"391","author":"Pavord","year":"2018","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01134","article-title":"Biological therapies of severe asthma and their possible effects on airway remodeling","volume":"11","author":"Kardas","year":"2020","journal-title":"Front Immunol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2020.10.035","article-title":"The relationship of asthma biologics to remission for asthma","volume":"9","author":"Menzies-Gow","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2019.12.006","article-title":"An expert consensus framework for asthma remission as a treatment goal","volume":"145","author":"Menzies-Gow","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1111\/all.14425","article-title":"EAACI biologicals guidelines-recommendations for severe asthma","volume":"76","author":"Agache","year":"2021","journal-title":"Allergy"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-022-02098-1","article-title":"Clinical remission in severe asthma: a pooled post hoc analysis of the patient journey with benralizumab","volume":"39","author":"Menzies-Gow","year":"2022","journal-title":"Adv Ther"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-021-01597-9","article-title":"REal worlD effectiveness and safety of mepolizumab in a multicentric Spanish cohort of asthma patients stratified by eosinophils: the REDES study","volume":"81","author":"Domingo Ribas","year":"2021","journal-title":"Drugs"},{"key":"B8","unstructured":"Mepolizumab (Nucala) prescribing information2022"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01444-2018","article-title":"Randomised controlled trials in severe asthma: selection by phenotype or stereotype","volume":"52","author":"Brown","year":"2018","journal-title":"Eur Respir J"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1111\/all.15382","article-title":"RELIght: A two-year REal-LIfe study of mepolizumab in patients with severe eosinophilic asTHma in Greece: Evaluating the multiple components of response","volume":"77","author":"Kallieri","year":"2022","journal-title":"Allergy"},{"key":"B11","doi-asserted-by":"publisher","first-page":"3997","DOI":"10.1016\/j.jaip.2021.06.041","article-title":"Defining a severe asthma super-responder: Findings from a Delphi process","volume":"9","author":"Upham","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B12","unstructured":"Global strategy for asthma management and prevention2022"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24032455","article-title":"Severe asthma remissions induced by biologics targeting IL5\/IL5r: Results from a multicenter real-life study","volume":"24","author":"Maglio","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2020.12.061","article-title":"Dupilumab treatment leads to clinical asthma remission in patients with uncontrolled moderate-to-severe asthma with type 2 inflammation","author":"Pavord","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2006.11.639","article-title":"Characterization of the severe asthma phenotype by the national heart, lung, and blood institute's severe asthma research program","volume":"119","author":"Moore","year":"2007","journal-title":"J Allergy Clin Immunol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.162.4.9909044","article-title":"Airway wall thickness in asthma assessed by computed tomography. relation to clinical indices","volume":"162","author":"Niimi","year":"2000","journal-title":"Am J Respir Crit Care Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1136\/thorax.57.3.242","article-title":"Correlation between the bronchial subepithelial layer and whole airway wall thickness in patients with asthma","volume":"57","author":"Kasahara","year":"2002","journal-title":"Thorax"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1513737","article-title":"Patterns of growth and decline in lung function in persistent childhood asthma","volume":"374","author":"McGeachie","year":"2016","journal-title":"N Engl J Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2020.00191","article-title":"Airway remodeling in asthma","volume":"7","author":"Hough","year":"2020","journal-title":"Front Med (Lausanne)"},{"key":"B20","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/j.clinthera.2011.05.044","article-title":"Use of biologics in rheumatoid arthritis: current and emerging paradigms of care","volume":"33","author":"Curtis","year":"2011","journal-title":"Clin Ther"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2015-000057","article-title":"Rheumatoid arthritis treatment: the earlier the better to prevent joint damage","volume":"1","author":"Monti","year":"2015","journal-title":"RMD Open"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-216655","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update","volume":"79","author":"Smolen","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"B23","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1016\/j.jaip.2017.12.019","article-title":"Asthma exacerbations associated with lung function decline in patients with severe eosinophilic asthma","volume":"6","author":"Ortega","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2019.04.020","article-title":"Increase in blood eosinophils during follow-up is associated with lung function decline in adult asthma","volume":"152","author":"Graff","year":"2019","journal-title":"Respir Med"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1701785","DOI":"10.1183\/13993003.01785-2017","article-title":"Predictors of accelerated decline in lung function in adult-onset asthma","volume":"51","author":"Coumou","year":"2018","journal-title":"Eur Respir J"},{"key":"B26","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/S2213-2600(19)30276-0","article-title":"Lung function decline in former smokers and low-intensity current smokers: a secondary data analysis of the NHLBI pooled cohorts study","volume":"8","author":"Oelsner","year":"2020","journal-title":"Lancet Respir Med"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2021.09.023","article-title":"Anti-interleukin-5 therapy is associated with attenuated lung function decline in severe eosinophilic asthma patients from the Belgian severe asthma registry","volume":"10","author":"Graff","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-022-02213-2","article-title":"Letter to the Editor regarding \"Clinical remission in severe asthma: A pooled Post hoc analysis of the patient journey with benralizumab\"","volume":"39","author":"Calzetta","year":"2022","journal-title":"Adv Ther"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.2147\/JAA.S321212","article-title":"Association between a type 2 inflammatory disease burden score and outcomes among patients with asthma","volume":"14","author":"Price","year":"2021","journal-title":"J Asthma Allergy"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1902420","DOI":"10.1183\/13993003.02420-2019","article-title":"Mepolizumab effectiveness and identification of super-responders in severe asthma","volume":"55","author":"Harvey","year":"2020","journal-title":"Eur Respir J"},{"key":"B31","doi-asserted-by":"publisher","first-page":"2263","DOI":"10.1016\/j.jaip.2020.02.042","article-title":"Development of the asthma impairment and risk questionnaire (AIRQ): a composite control measure","volume":"8","author":"Murphy","year":"2020","journal-title":"J Allergy Clin Immunol Pract"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1150162\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,12]],"date-time":"2023-04-12T07:02:54Z","timestamp":1681282974000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1150162\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,12]]},"references-count":31,"alternative-id":["10.3389\/fimmu.2023.1150162"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1150162","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,12]]},"article-number":"1150162"}}